The presence of TP53 mutations in AML patients with complex cytogenetic aberrations can regularly be observed in combination with a monosomal karyotype and is associated with age, a reduced response rate and worse outcome (Rücker et al. 2012). The gene discussed is TP53; the disease is acute myeloid leukemia.